Clinical Trial Update: CD133+ Cell Therapy for Refractory Coronary Heart Disease [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial of CD133+ cell therapy for refractory coronary artery disease is being conducted. The status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• CD133+ cell therapy

Snippet

Sponsor: Hospital y Clinica OCA, S.A. de C.V. | Conditions: Coronary Artery Disease | Phase 1, Phase 2 | Status: UNKNOWN